Leaflet ZAVESCA 100mg capsules

Product code:
W51776001
Quantity:
84
Indicated for:
Gaucher disease; Niemann-Pick type C disease
Route of administration:
oral
Substance:
miglustat (enzyme inhibitor)
ATC
A16AX06 — Alimentary tract and metabolism | Other alimentary tract and metabolism products | Other alimentary tract and metabolism products | Various alimentary tract and metabolism products
Miglustat is a glucosylceramide synthase inhibitor used for the treatment of type 1 Gaucher disease and Niemann-Pick type C disease. It works by reducing the production of glycosphingolipids, which accumulate in cells due to these conditions.

The medication is taken orally, usually three times daily, with the dose adjusted based on the patient's weight and response to treatment. Common side effects include diarrhea, flatulence, abdominal pain, and weight loss.

Miglustat is contraindicated in patients with severe renal impairment or hypersensitivity to the active substance. Its use also requires careful monitoring of gastrointestinal function and body weight.

This medication is an important option for managing lysosomal storage disorders, helping to alleviate symptoms and slow disease progression.

General data about ZAVESCA 100mg

Substance:
miglustat
Date of latest medicines list:
01-07-2013
Product code:
W51776001
Concentration:
100mg
Pharmaceutical form:
capsules
Quantity:
84
Product type:
Original
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.